VRTX
VERTEX PHARMACEUTICALS INC / MA
NASDAQ · Healthcare · Biotechnology · US
$508.14
−1.59%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$517.75
From 52W high−8.93%
Volume2.42M
Market cap$128.79B
P/E (TTM)29.3x
P/S (TTM)10.2x
Div yield—
Key dataSep 18, 2026
Open
$517.75
From 52W high
−8.93%
Volume
2.42M
Market cap
$128.79B
ValuationView details →
P/E (Fwd)
26.4x
EV/EBITDA
22.6x
P/E (TTM)
29.3x
RSI (14)
40.3
MomentumView details →
1D Return
−1.59%
YTD Return
+11.71%
SummaryUpdated Jun 1, 2026
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a Boston-based biotechnology company founded in 1989 and publicly traded since 1991. The company has evolved from a research-focused biotech startup into a leading commercial biopharmaceutical company, primarily known for developing breakthrough treatments for cystic fibrosis. Over its three-decade history, Vertex has transformed from having no approved products to generating over $11 billion in annual revenue, establishing itself as a dominant force in rare disease therapeutics with an expanding pipeline across multiple therapeutic areas including pain management, diabetes, kidney diseases, and blood disorders.
Similar companies
Latest newsMore news →
Vertex Pharmaceuticals raised its full-year revenue guidance to $13.1 billion to $13.2 billion from a previous range of $12.95 billion to $13.1 billion.2d agoVertex Pharmaceuticals reported second-quarter results with revenue up 12% year over year to $3.33 billion and earnings per share up 8% year over year to $4.31.2d agoThe U.S. Court of Appeals for the D.C. Circuit ruled in Vertex Pharmaceuticals Inc. v. U.S. Department of Health and Human Services, broadly construing the Anti-Kickback Statute, reversing OIG's finding that Vertex's Fertility Support Program violated the Beneficiary Inducement Statute, and striking down OIG's advisory opinion timing regulations.6d ago